Want to see ADXN full AI Analyst Report?
Addex Therapeutics (ADXN) AI Stock Analysis
Addex Therapeutics
(NASDAQ:ADXN)
The overall score is low because financial performance is very weak, with minimal revenue, ongoing cash burn, and erosion of equity despite low debt. Technical indicators reinforce this cautious view, showing a clear downtrend and only modest signs of being oversold, while valuation is not compelling given the negative P/E and lack of dividend. The latest earnings call offers some offset through extended runway, regained rights, and advancing programs, but these positives remain highly dependent on continued external financing and successful clinical execution.
Addex Therapeutics (ADXN) vs. SPDR S&P 500 ETF (SPY)
- Market Cap
- $3.81M
- Dividend Yield
- ―
- Average Volume (3M)
- 162.12K
- Price to Earnings (P/E)
- -0.5
- Beta (1Y)
- 1.10
- Revenue Growth
- -45.76%
- EPS Growth
- -3.77%
- Country
- US
- Employees
- 3
- Sector
- Healthcare
- Sector Strength
- 51
- Industry
- Biotechnology
Addex Therapeutics Business Overview & Revenue Model
Company Description
Addex Therapeutics Ltd, a biopharmaceutical firm in a developmental phase, operates out of Switzerland, focusing on the discovery, advancement, and commercialization of small-molecule drugs targeting central nervous system (CNS) disorders. Their core...
How the Company Makes Money
Addex Therapeutics primarily makes money through partnering and collaboration arrangements rather than commercial product sales (as a clinical-stage company). Its revenue model typically consists of: (1) upfront payments received when entering licens...
Addex Therapeutics Earnings Call Summary
The call was predominantly positive, highlighting a $2.8 million financing, cash runway into Q4 2027, regained rights to the GABAB PAM platform, multiple advancing preclinical and clinical programs, and encouraging chronic cough and substance use disorder data. Offsetting factors included the CHF 0.8 million half-year cash balance, CHF 1.2 million of operating cash use, a stable CHF 3.4 million net loss, increased share of Neurosterix losses, and the need to secure financing before advancing certain programs.
Q2-2026 Updates
Positive Updates
Negative Updates
Company Guidance
Addex said the GABAB PAM substance use disorder candidate is ready for IND filing and phase I clinical trials, with the next milestone being the filing of an IND, while IND enabling studies for the chronic cough program are “planned and ready to start subject to securing financing”; it expects phase I data from Neurosterix’s NTX-253 program in Q4 this year, NTX-529 IND-enabling studies should start shortly, NTX-819 is expected to complete IND-enabling studies in the coming months, and it continues to prepare dipraglurant for phase II in post-stroke recovery. The company said it raised $2.8 million in Q3 through its ATM facility, providing cash runway into Q4 2027, and that patents filed in 2024, if granted, are expected to expire in 2044.
Addex Therapeutics Financial Statement Overview
Summary
Revenue has collapsed to a very low level, margins are deeply negative, and the company continues to post sizable operating and net losses, with equity and assets eroding over time despite low leverage and some narrowing of losses and cash burn.
Income Statement
27NegativeBalance Sheet
35NegativeCash Flow
32Negative| Breakdown | TTM | Mar 2026 | Mar 2025 | Mar 2024 | Dec 2022 | Dec 2021 |
|---|---|---|---|---|---|---|
Income Statement | ||||||
| Total Revenue | 47.57K | 29.97K | 404.10K | 1.61M | 1.42M | 2.92M |
| Gross Profit | -13.68K | 29.97K | 404.10K | 1.61M | 1.42M | 2.92M |
| EBITDA | -5.72M | -6.83M | -4.65M | -2.19M | -10.45M | -14.94M |
| Net Income | -6.86M | -6.73M | 7.06M | -10.56M | -20.80M | -15.35M |
Balance Sheet | ||||||
| Total Assets | 3.48M | 6.37M | 10.68M | 4.64M | 8.28M | 22.54M |
| Cash, Cash Equivalents and Short-Term Investments | 767.33K | 1.64M | 3.35M | 3.87M | 6.96M | 20.50M |
| Total Debt | 77.50K | 34.73K | 41.99K | 344.34K | 373.13K | 482.01K |
| Total Liabilities | 1.57M | 1.60M | 1.00M | 3.50M | 3.37M | 5.61M |
| Stockholders Equity | 1.91M | 4.77M | 9.68M | 1.15M | 4.91M | 16.93M |
Cash Flow | ||||||
| Free Cash Flow | -2.38M | -2.08M | -5.37M | -8.00M | -16.44M | -14.74M |
| Operating Cash Flow | -2.38M | -2.08M | -5.37M | -7.99M | -16.44M | -14.71M |
| Investing Cash Flow | 51.03K | -650.08K | 4.65M | -6,842 | 2,972 | -30.31K |
| Financing Cash Flow | 800.71K | 1.13M | 104.92K | 5.26M | 3.10M | 16.40M |
Addex Therapeutics Technical Analysis
Price Trends
Market Momentum
Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For ADXN, the sentiment is Neutral. The current price of 3.09 is above the 20-day moving average (MA) of 3.00, below the 50-day MA of 3.33, and below the 200-day MA of 5.79, indicating a neutral trend. The MACD of -0.12 indicates Negative momentum. The RSI at 49.14 is Neutral, neither overbought nor oversold. The STOCH value of 50.77 is Neutral, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Neutral sentiment for ADXN.
Addex Therapeutics Risk Analysis
Addex Therapeutics disclosed 54 risk factors in its most recent earnings report. Addex Therapeutics reported the most risks in the "Finance & Corporate" category.
Latest Risks Added
1 New RiskAddex Therapeutics Peers Comparison
Overall Rating
KPRX43Neutral- ADXN42Neutral
HCWB42Neutral
NCNA42Neutral
XBIO42Neutral
Financial Indicators
| Name | Overall Rating | Market Cap | P/E Ratio | ROE | Dividend Yield | Revenue Growth | EPS Growth |
|---|---|---|---|---|---|---|---|
| Sector * | 51Neutral | $7.86B | -0.30 | -43.30% | 2.27% | 22.53% | -2.21% |
| KPRX | 43Neutral | $6.90M | -0.62 | -63.39% | ― | ― | 19.38% |
| ADXN | 42Neutral | $3.50M | -0.48 | -172.76% | ― | -45.76% | -3.77% |
| HCWB | 42Neutral | $2.46M | -0.02 | -142.16% | ― | 707.02% | 70.52% |
| NCNA | 42Neutral | $4.35M | -0.25 | -41.95% | ― | ― | 99.50% |
| XBIO | 42Neutral | $4.80M | -1.72 | -40.62% | ― | 33.30% | 40.59% |
* Healthcare Sector Average
Performance Comparison
| Show on chart | Ticker | Company Name | Price | Change | % Change |
|---|---|---|---|---|---|
| ADXN | Addex Therapeutics Ltd (ADR) | 3.09 | -5.62 | -64.52% | |
| KPRX | Kiora Pharmaceuticals, Inc. | 1.56 | -0.91 | -36.84% | |
| XBIO | Xenetic Biosciences, Inc. | 2.05 | -1.07 | -34.29% | |
| NCNA | Nucana Plc | 1.01 | -2.93 | -74.37% | |
| CELZ | Creative Medical Technology Holdings, Inc. | 0.66 | -2.34 | -78.17% | |
| HCWB | Hcw Biologics, Inc. | 1.10 | -20.50 | -94.91% |
Disclaimer
This AI Analyst Stock Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in stocks carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.
Date of analysis: Oct 01, 2026